Tuberculosis (TB) rates are declining globally, but the impact on immigration screening programs – and the individuals they aim to protect – is a complex question. New research from McGill University and collaborating institutions projects a significant decrease in both TB infection prevalence and the risk of developing active TB among immigrants arriving in low-incidence countries like Canada, the US, UK, and Australia. This isn’t simply a matter of fewer cases; it signals a potential shift in how we approach TB control, demanding a re-evaluation of resource allocation and screening strategies.
- Declining Risk: The study projects substantial declines in TB infection prevalence among immigrants from key source countries (China, India, the Philippines, and Vietnam) by 2050.
- Shifting Cost-Effectiveness: Current TB screening programs for immigrants may become less cost-effective as overall infection rates fall.
- Targeted Approaches Needed: Future TB control strategies will likely require more targeted approaches, focusing on high-risk individuals rather than broad-scale screening.
For decades, TB has disproportionately affected immigrant populations in low-incidence countries, as individuals arriving from high-transmission areas often carry latent infections that can reactivate. This has led to widespread screening programs aimed at identifying and treating these latent infections. However, the researchers demonstrate that the epidemiological landscape is changing. Using detailed modeling based on historical and projected TB incidence data, they estimate that the annual risk of infection (ARI) is decreasing in major source countries. This decline directly translates to lower rates of infection among new immigrants.
The study meticulously analyzes data from 168 countries, with a particular focus on China, India, the Philippines, and Vietnam – nations accounting for over half of new immigrants to the four studied receiving countries. The modeling incorporates age distribution of immigrants, projecting how changes in TB transmission will affect immunoreactivity prevalence (a measure of infection) and the risk of progressing to active TB disease. Importantly, the researchers also considered the possibility of immunoreactivity reversion – where a positive test result reverts to negative – and found that accounting for this phenomenon increases estimated TB risks, highlighting the complexities of accurate diagnosis.
The Forward Look: Adapting to a Changing Landscape
The implications of these findings are significant. As TB rates continue to fall in source countries, the cost-effectiveness of universal screening programs will inevitably diminish. Resources currently allocated to screening large numbers of immigrants may be better directed towards more targeted interventions. This could include focusing on individuals with known risk factors (e.g., HIV co-infection, close contacts of active TB cases), or prioritizing screening for recent immigrants – those within the first two years of arrival, when the risk of progression is highest. The study’s projections suggest that the benefits of screening will be most pronounced for younger age groups, as they have had less cumulative exposure and stand to gain the most from preventative treatment.
However, the researchers caution against complacency. The potential for immunoreactivity reversion underscores the need for continued vigilance and accurate diagnostic testing. Furthermore, global events – such as disruptions to TB control programs due to funding cuts or geopolitical instability – could reverse these positive trends. The study emphasizes the importance of ongoing monitoring and evaluation of TB screening programs to ensure they remain efficient and effective in a dynamic epidemiological environment. The future of TB control in immigration settings will require a flexible, data-driven approach, adapting to the evolving risk profile of immigrant populations and maximizing the impact of limited resources. The shift isn’t about abandoning screening, but about *smart* screening – a move towards precision public health.
Ms. Machado works in health economics and outcomes research McGill University, Montreal, Quebec, Canada. Her research interests focus on generating evidence to support health equity and access to care, particularly among vulnerable populations.
Author contributions: J.R.C. and K.S. initially conceptualized the study; M.M., A.E.J., and J.R.C. conducted analysis; M.M. and J.R.C. wrote the first draft; and all authors contributed to study development and interpretation and revised the final draft. All authors meet ICMJE criteria for authorship and have seen and approved the final submitted version.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
